Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Foghorn Therapeutics Inc. - Common Stock
(NQ:
FHTX
)
2.020
-0.900 (-30.82%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Foghorn Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
August 05, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
May 22, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
May 14, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
May 05, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
May 01, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
April 28, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday
↗
April 23, 2025
Via
Benzinga
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
April 15, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
↗
April 01, 2025
Via
Benzinga
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
March 25, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
March 06, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
February 04, 2025
Via
Benzinga
This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
January 30, 2025
Via
Benzinga
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
January 13, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
December 16, 2024
Via
Benzinga
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower
↗
December 16, 2024
Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program.
Via
Benzinga
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
December 16, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
November 12, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
November 04, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
October 10, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in the BMO Oncology Summit
October 01, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
September 03, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
August 28, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
August 19, 2024
Via
Benzinga
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
↗
August 19, 2024
Via
Benzinga
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q2 2024
↗
August 08, 2024
FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
August 08, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
May 28, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
May 22, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
May 20, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
